Australia markets closed

ArriVent BioPharma, Inc. (AVBP)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
15.44-0.10 (-0.64%)
At close: 04:00PM EDT
15.44 0.00 (0.00%)
After hours: 04:20PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close15.54
Open16.00
Bid15.39 x 200
Ask15.65 x 100
Day's range15.40 - 16.47
52-week range14.35 - 25.95
Volume53,086
Avg. volume198,398
Market cap517.144M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est31.50
  • GlobeNewswire

    ArriVent Appoints Kristine Peterson to its Board of Directors

    NEWTON SQUARE, Pa., April 22, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc., a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Kristine Peterson to its Board of Directors. Ms. Peterson brings over 30 years of biopharmaceutical leadership experience, and currently serves on the Boards of public companies Immunocore, Inc. and Enanta Pharmaceuticals. “We are thrilled for Kris to join our Boa

  • GlobeNewswire

    ArriVent BioPharma Reports Full Year 2023 Financial Results

    Company progresses the development of furmonertinib with a data readout planned for 2024Furmonertinib granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration Completed $201 million initial public offering (“IPO”) in January 2024 NEWTOWN SQUARE, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“Company” or “ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, to